Decreased tumorigenesis in mice with a Kras point mutation at C118

Nature Communications

Volumn 5, Issue , 2014, Pages

  Huang, Lu ^a   Carney, John ^a   Cardona, Diana M ^a   Counter, Christopher M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; URETHAN; CARCINOGEN; KRAS2 PROTEIN, MOUSE; PROTEIN P21;

ALLELE; ENDOGENOUS GROWTH; MUTATION; REDOX CONDITIONS; RODENT; TUMOR;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SIZE; CONTROLLED STUDY; FEMALE; GENOTYPE; LUNG ADENOMA; LUNG CARCINOGENESIS; LUNG PARENCHYMA; MOUSE; NONHUMAN; POINT MUTATION; ANIMAL; C57BL MOUSE; CARCINOGENESIS; CHEMICALLY INDUCED; GENETICS; LUNG TUMOR; MALE; PHYSIOLOGY; PROCEDURES; SITE DIRECTED MUTAGENESIS; TRANSGENIC MOUSE;

MURINAE; MUS;

ALLELES; ANIMALS; CARCINOGENESIS; CARCINOGENS; FEMALE; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTAGENESIS, SITE-DIRECTED; POINT MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS); URETHANE;

EID: 84923289821     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6410     Document Type: Article

References (43)

1. Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761-774 (2011).
2. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11-22 (2003).
3. Gysin, S., Salt, M., Young, A. & McCormick, F. Therapeutic strategies for targeting ras proteins. Genes Cancer 2, 359-372 (2011).
4. Bos, J. L., Rehmann, H. &Wittinghofer, A. GEFs and GAPs: critical elements in the control of small G proteins. Cell 129, 865-877 (2007).
5. Vigil, D., Cherfils, J., Rossman, K. L. & Der, C. J. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat. Rev. Cancer 10, 842-857 (2010).
6. Lander, H. M. et al. Redox regulation of cell signalling. Nature 381, 380-381 (1996).
7. Raines, K. W., Bonini, M. G. & Campbell, S. L. Nitric oxide cell signaling: S-nitrosation of Ras superfamily GTPases. Cardiovas. Res. 75, 229-239 (2007).
8. Hobbs, G. A., Bonini, M. G., Gunawardena, H. P., Chen, X. & Campbell, S. L. Glutathiolated Ras: characterization and implications for Ras activation. Free Radic. Biol. Med. 57, 221-229 (2013).
9. Ibiza, S. et al. Endothelial nitric oxide synthase regulates N-Ras activation on the Golgi complex of antigen-stimulated T cells. Proc. Natl. Acad. Sci. USA 105, 10507-10512 (2008).
10. Lander, H. M. et al. A molecular redox switch on p21(ras). Structural basis for the nitric oxide-p21(ras) interaction. J. Biol. Chem. 272, 4323-4326 (1997).
11. Lander, H. M., Jacovina, A. T., Davis, R. J. & Tauras, J. M. Differential activation of mitogen-activated protein kinases by nitric oxide-related species. J. Biol. Chem. 271, 19705-19709 (1996).
12. Raines, K. W., Cao, G. L., Lee, E. K., Rosen, G. M. & Shapiro, P. Neuronal nitric oxide synthase-induced S-nitrosylation of H-Ras inhibits calcium ionophore-mediated extracellular-signal-regulated kinase activity. Biochem. J. 397, 329-336 (2006).
13. Switzer, C. H. et al. Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer. Breast Cancer Res. 14, R125 (2012).
14. Lin, Y. F., Raab-Graham, K., Jan, Y. N. & Jan, L. Y. NO stimulation of ATP-sensitive potassium channels: Involvement of Ras/mitogen-activated protein kinase pathway and contribution to neuroprotection. Proc. Natl Acad. Sci. USA 101, 7799-7804 (2004).
15. Lee, M. & Choy, J. C. Positive feedback regulation of human inducible nitric-oxide synthase expression by Ras protein S-nitrosylation. J. Biol. Chem. 288, 15677-15686 (2013).
16. Batista, W. et al. S-Nitrosoglutathione and endothelial nitric oxide synthasederived nitric oxide regulate compartmentalized ras S-nitrosylation and stimulate cell proliferation. Antioxid. Redox Signal. 18, 221-238 (2013).
17. Adachi, T. et al. S-Glutathiolation of Ras mediates redox-sensitive signaling by angiotensin II in vascular smooth muscle cells. J. Biol. Chem. 279, 29857-29862 (2004).
18. Clavreul, N. et al. S-Glutathiolation by peroxynitrite of p21ras at cysteine-118 mediates its direct activation and downstream signaling in endothelial cells. FASEB J. 20, 518-520 (2006).
19. Dudzinski, D. M., Igarashi, J., Greif, D. & Michel, T. The regulation and pharmacology of endothelial nitric oxide synthase. Annu. Rev. Pharmacol. Toxicol. 46, 235-276 (2006).
20. Lim, K. H., Ancrile, B. B., Kashatus, D. F. & Counter, C. M. Tumour maintenance is mediated by eNOS. Nature 452, 646-649 (2008).
21. Sarkisian, C. J. et al. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat. Cell Biol. 9, 493-505 (2007).
22. Heo, J. & Campbell, S. L. Mechanism of p21Ras S-nitrosylation and kinetics of nitric oxide-mediated guanine nucleotide exchange. Biochemistry 43, 2314-2322 (2004).
23. Mott, H. R., Carpenter, J. W. & Campbell, S. L. Structural and functional analysis of a mutant Ras protein that is insensitive to nitric oxide activation. Biochemistry 36, 3640-3644 (1997).
24. Williams, J. G., Pappu, K. & Campbell, S. L. Structural and biochemical studies of p21Ras S-nitrosylation and nitric oxide-mediated guanine nucleotide exchange. Proc. Natl Acad. Sci. USA 100, 6376-6381 (2003).
25. Patek, C. E. et al. Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis. Exp. Cell Res. 314, 1105-1114 (2008).
26. To, M. D. et al. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat. Genet. 40, 1240-1244 (2008).
27. Dimmeler, S. et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399, 601-605 (1999).
28. Fulton, D. et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399, 597-601 (1999).
29. Koera, K. et al. K-ras is essential for the development of the mouse embryo. Oncogene 15, 1151-1159 (1997).
30. You, M., Candrian, U., Maronpot, R. R., Stoner, G. D. & Anderson, M. W. Activation of the Ki-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc. Natl Acad. Sci. USA 86, 3070-3074 (1989).
31. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
32. Manenti, G. et al. Haplotype sharing suggests that a genomic segment containing six genes accounts for the pulmonary adenoma susceptibility 1 (Pas1) locus activity in mice. Oncogene 23, 4495-4504 (2004).
33. Stathopoulos, G. T. et al. Epithelial NF-kappaB activation promotes urethaneinduced lung carcinogenesis. Proc. Natl Acad. Sci. USA 104, 18514-18519 (2007).
34. Avanzo, J. L. et al. Increased susceptibility to urethane-induced lung tumors in mice with decreased expression of connexin43. Carcinogenesis 25, 1973-1982 (2004).
35. Zhang, Z. et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat. Genet. 29, 25-33 (2001).
36. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248 (2001).
37. Hocker, H. J. et al. Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function. Proc. Natl Acad. Sci. USA 110, 10201-10206 (2013).
38. Huang, H. et al. Oncogenic K-Ras requires activation for enhanced activity. Oncogene 33, 532-535 (2014).
39. Jeng, H. H., Taylor, L. J. & Bar-Sagi, D. Sos-mediated cross-activation of wildtype Ras by oncogenic Ras is essential for tumorigenesis. Nat. Commun. 3, 1168 (2012).
40. Fukumura, D., Kashiwagi, S. & Jain, R. K. The role of nitric oxide in tumour progression. Nat. Rev. Cancer 6, 521-534 (2006).
41. Sakano, K., Oikawa, S., Hiraku, Y. & Kawanishi, S. Metabolism of carcinogenic urethane to nitric oxide is involved in oxidative DNA damage. Free Radic. Biol. Med. 33, 703-714 (2002).
42. Kisley, L. R. et al. Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Res. 62, 6850-6856 (2002).
43. O'Hayer, K. M. & Counter, C. M. A genetically defined normal human somatic cell system to study ras oncogenesis in vivo and in vitro. Methods Enzymol. 407, 637-647 (2006).